| Summary of Segment Profit or Loss, Including Significant Expenses |
The table below is a summary of the segment profit or loss, including significant expenses, in thousands:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
September 30, |
|
Nine Months Ended
September 30, |
|
|
2025 |
|
|
2024 |
|
2025 |
|
|
2024 |
|
Collaboration revenue |
$ |
20,750 |
|
|
$ |
— |
|
$ |
50,146 |
|
|
$ |
— |
|
Less: |
|
|
|
|
|
|
|
|
|
|
Ziftomenib-related costs |
|
40,320 |
|
|
|
18,993 |
|
|
107,851 |
|
|
|
52,335 |
|
Darlifarnib (KO-2806)-related costs |
|
8,494 |
|
|
|
5,178 |
|
|
19,871 |
|
|
|
13,026 |
|
Tipifarnib-related costs |
|
443 |
|
|
|
721 |
|
|
2,578 |
|
|
|
3,560 |
|
Discovery stage program-related costs |
|
1,744 |
|
|
|
1,769 |
|
|
5,323 |
|
|
|
4,950 |
|
Research and development personnel costs and other expenses |
|
13,695 |
|
|
|
11,474 |
|
|
41,790 |
|
|
|
32,611 |
|
Share-based compensation expense |
|
10,965 |
|
|
|
8,324 |
|
|
25,756 |
|
|
|
25,266 |
|
Other segment expenses(1) |
|
25,086 |
|
|
|
13,425 |
|
|
64,340 |
|
|
|
38,992 |
|
Total operating expenses |
|
100,747 |
|
|
|
59,884 |
|
|
267,509 |
|
|
|
170,740 |
|
Other income (expenses) |
|
|
|
|
|
|
|
|
|
|
Interest and other income |
|
6,274 |
|
|
|
5,892 |
|
|
21,088 |
|
|
|
17,190 |
|
Interest expense |
|
(393 |
) |
|
|
(412 |
) |
|
(1,166 |
) |
|
|
(1,216 |
) |
Income tax expense |
|
— |
|
|
|
— |
|
|
(226 |
) |
|
|
— |
|
Segment and net loss |
$ |
(74,116 |
) |
|
$ |
(54,404 |
) |
$ |
(197,667 |
) |
|
$ |
(154,766 |
) |
(1)Other segment expenses are comprised of general and administrative expenses, excluding share-based compensation expense, which is shown separately.
|